|
Synonyms: HM-12525A | HM12525A | JNJ-64565111 | JNJ64565111 | LAPS-GLP-1/GCG | MK-6024 | MK6024
Compound class:
Peptide
Comment: Efinopegdutide (MK-6024, formerly HM-12525A and JNJ-64565111) is a once-weekly injectable, dual agonist of the GLP-1 and glucagon receptors [3]. Structurally is a conjugate of an oxyntomodulin analogue and the constant region (Fc) of human IgG4, joined via a 10 kDa polyethylene glycol (PEG) linker. The INN record shows that the amino acid sequence of the oxyntomodulin analogue component is HBQGTFTSDYSKYLDEKRAKEFVQWLMNTC-NH2, where B2 is 2-methylalanyl (2-aminoisobutyryl, Aib). An amide bond between E and K cyclises the peptide.
|
| No information available. |
Summary of Clinical Use ![]() |
| As JNJ-64565111, efinopegdutide was progressed as an anti-diabetes/anti-obesiy clinical candidate [1-2,5]. It was subsequently evaluated for potential to reduce liver fat content in patients with metabolic dysfunction-associated steatohepatitis (MASH) [7,9]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04944992 | A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) | Phase 2 Interventional | Merck Sharp & Dohme LLC | 8 | |
| NCT05877547 | A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) | Phase 2 Interventional | Merck Sharp & Dohme LLC | 4 | |
| NCT03586830 | A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus | Phase 2 Interventional | Janssen Research & Development, LLC | 2 | |